Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Carl A K Borrebaeck; Ann-Christin Malmborg; Mats Ohlin

doi:10.1016/0167-5699(93)90259-N

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Carl A K Borrebaeck, Ann-Christin Malmborg, Mats Ohlin

Department of Immunotechnology

Research output: Contribution to journal › Article › peer-review

Abstract

Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.

Original language	English
Pages (from-to)	477-479
Number of pages	3
Journal	Immunology Today
Volume	14
Issue number	10
DOIs	https://doi.org/10.1016/0167-5699(93)90259-N
Publication status	Published - 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0167-5699(93)90259-N

Cite this

@article{39816fd2df094b86bc02a4e8bda83eff,

title = "Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?",

abstract = "Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.",

author = "Borrebaeck, \{Carl A K\} and Ann-Christin Malmborg and Mats Ohlin",

year = "1993",

doi = "10.1016/0167-5699(93)90259-N",

language = "English",

volume = "14",

pages = "477--479",

journal = "Immunology Today",

issn = "0167-5699",